Do analysts rate GRDX or BCAB?

BioAtla has a consensus price target of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GRDX or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% BioAtla N/A N/A -325.64%

Do analysts prefer BCAB or TXMD?

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts clearly believe BioAtla is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AYTU or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. BioAtla's return on equity of 0.00% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% BioAtla N/A N/A -325.64%

Which has preferable earnings and valuation, KZIA or BCAB?

Novogen has higher earnings, but lower revenue than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 482.52 -$13.41M N/A N/A BioAtla $2M 2.79 -$59.61M -$41.72 N/A

Is KZIA or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A BioAtla N/A N/A -325.64%

Is JSPR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% BioAtla N/A N/A -325.64%

BioAtla (BCAB) Competitors

$3.37 -0.09 (-2.60%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$3.37 0.00 (0.00%)

As of 07/24/2026 04:10 PM Eastern

Compare

BCAB vs. GRDX, TXMD, AYTU, KZIA, and JSPR

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include Entero Therapeutics (GRDX), TherapeuticsMD (TXMD), Aytu BioPharma (AYTU), Novogen (KZIA), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and BioAtla (NASDAQ:BCAB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

BioAtla has a consensus price target of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entero Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Entero Therapeutics has higher earnings, but lower revenue than BioAtla. Entero Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	282.24	-$6.39M	-$1.88	N/A
BioAtla	$2M	2.79	-$59.61M	-$41.72	N/A

BioAtla's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
BioAtla	N/A	N/A	-325.64%

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 1.87 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Very Positive
BioAtla	Very Positive

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BioAtla beats Entero Therapeutics on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to TherapeuticsMD?

BioAtla (NASDAQ:BCAB) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, BioAtla and BioAtla both had 1 articles in the media. BioAtla's average media sentiment score of 1.87 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Very Positive
TherapeuticsMD	Very Positive

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	2.79	-$59.61M	-$41.72	N/A
TherapeuticsMD	$3.02M	7.89	-$570K	$0.06	34.33

BioAtla has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to BioAtla's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat BioAtla's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
TherapeuticsMD	5.34%	0.32%	0.23%

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts clearly believe BioAtla is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats BioAtla on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 397.69%. BioAtla has a consensus price target of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aytu BioPharma has higher revenue and earnings than BioAtla. Aytu BioPharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
BioAtla	$2M	2.79	-$59.61M	-$41.72	N/A

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioAtla has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. BioAtla's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
BioAtla	N/A	N/A	-325.64%

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. BioAtla's average media sentiment score of 1.87 beat Aytu BioPharma's score of 0.44 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
BioAtla	Very Positive

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

BioAtla beats Aytu BioPharma on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to Novogen?

Novogen (NASDAQ:KZIA) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Novogen presently has a consensus target price of $25.80, indicating a potential upside of 110.44%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 5,834.72%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Novogen has higher earnings, but lower revenue than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	482.52	-$13.41M	N/A	N/A
BioAtla	$2M	2.79	-$59.61M	-$41.72	N/A

30.9% of Novogen shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Novogen and Novogen both had 1 articles in the media. Novogen's average media sentiment score of 1.89 beat BioAtla's score of 1.87 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Very Positive
BioAtla	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
BioAtla	N/A	N/A	-325.64%

Summary

Novogen beats BioAtla on 7 of the 11 factors compared between the two stocks.

How does BioAtla compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Jasper Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 1,643.17%. BioAtla has a consensus target price of $200.00, suggesting a potential upside of 5,834.72%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Jasper Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Jasper Therapeutics' score of 0.63 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
BioAtla	Very Positive

BioAtla's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
BioAtla	N/A	N/A	-325.64%

79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jasper Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

BioAtla has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
BioAtla	$2M	2.79	-$59.61M	-$41.72	N/A

Summary

Jasper Therapeutics and BioAtla tied by winning 7 of the 14 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.58M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.08	21.48	27.14	23.64
Price / Sales	2.79	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-0.12	7.88	10.28	6.07
Net Income	-$59.61M	$23.86M	$3.60B	$331.99M
7 Day Performance	-14.05%	-3.82%	-1.27%	-0.63%
1 Month Performance	-5.07%	-2.61%	-0.37%	-2.00%
1 Year Performance	-81.00%	32.79%	18.30%	13.62%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	2.4416 of 5 stars	$3.37 -2.6%	$200.00 +5,834.7%	-82.1%	$5.58M	$2M	N/A	60	Positive News Gap Down
GRDX Entero Therapeutics	1.455 of 5 stars	$3.52 +9.8%	N/A	N/A	$24.29M	$40K	N/A	9	Gap Up
TXMD TherapeuticsMD	1.7263 of 5 stars	$2.07 -1.9%	N/A	+80.7%	$23.95M	$3.02M	34.50	420
AYTU Aytu BioPharma	2.0461 of 5 stars	$2.18 +0.9%	$10.75 +393.1%	-18.5%	$23.39M	$66.38M	N/A	160
KZIA Novogen	2.2148 of 5 stars	$14.02 +3.5%	$25.80 +84.0%	+23.1%	$23.13M	$30K	N/A	12	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. GRDX, TXMD, AYTU, KZIA, and JSPR

How does BioAtla compare to Entero Therapeutics?

Summary

How does BioAtla compare to TherapeuticsMD?

Summary

How does BioAtla compare to Aytu BioPharma?

Summary

How does BioAtla compare to Novogen?

Summary

How does BioAtla compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. GRDX, TXMD, AYTU, KZIA, and JSPR

How does BioAtla compare to Entero Therapeutics?

Do analysts rate GRDX or BCAB?

Which has more risk & volatility, GRDX or BCAB?

Which has higher earnings and valuation, GRDX or BCAB?

Is GRDX or BCAB more profitable?

Does the media favor GRDX or BCAB?

Do institutionals & insiders hold more shares of GRDX or BCAB?

Summary

How does BioAtla compare to TherapeuticsMD?

Does the media refer more to BCAB or TXMD?

Do insiders & institutionals believe in BCAB or TXMD?

Which has stronger valuation & earnings, BCAB or TXMD?

Which has more volatility and risk, BCAB or TXMD?

Is BCAB or TXMD more profitable?

Do analysts prefer BCAB or TXMD?

Summary

How does BioAtla compare to Aytu BioPharma?

Do analysts recommend AYTU or BCAB?

Which has higher valuation & earnings, AYTU or BCAB?

Do insiders and institutionals believe in AYTU or BCAB?

Is AYTU or BCAB more profitable?

Does the media prefer AYTU or BCAB?

Which has more risk and volatility, AYTU or BCAB?

Summary

How does BioAtla compare to Novogen?

Which has more volatility and risk, KZIA or BCAB?

Do analysts recommend KZIA or BCAB?

Which has preferable earnings and valuation, KZIA or BCAB?

Do institutionals & insiders believe in KZIA or BCAB?

Does the media prefer KZIA or BCAB?

Is KZIA or BCAB more profitable?

Summary

How does BioAtla compare to Jasper Therapeutics?

Do analysts recommend JSPR or BCAB?

Does the media prefer JSPR or BCAB?

Is JSPR or BCAB more profitable?

Do insiders and institutionals hold more shares of JSPR or BCAB?

Which has more volatility & risk, JSPR or BCAB?

Which has better valuation & earnings, JSPR or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools